加利福尼亚州欧文市 - Edwards Lifesciences (NYSE:EW) 公布的第三季度盈利超过分析师预期，主要得益于其经导管二尖瓣和三尖瓣治疗（TMTT）业务的强劲增长。周四公布业绩后，该公司股价上涨4.19%。

Edwards Lifesciences stock popped late Thursday after the heart devices maker beat third-quarter profit expectations and kept ...

Edwards maintained its prior guidance for full-year sales growth of 8-10%, and expects Q4 sales of $1.33 billion to $1.39 ...

Edwards Lifesciences on Thursday forecast fourth-quarter sales below Wall Street estimates, hurt by softer demand and fierce ...

Wedgewood Partners, an investment management company, released its third-quarter 2024 investor letter. A copy of the letter ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Edwards Lifesciences Corp. (EW) on Thursday reported third-quarter earnings of $3.07 billion. On a per-share basis, the Irvine, California-based company ...

After Losing Over $16 Billion Of Market Capitalization Edwards Lifesciences (EW) Faces Investor Class Action - Hagens Berman ...

Levi & Korsinsky Notifies Edwards Lifesciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline ...

Morgan Stanley保持中性立场，目标价为70美元，注意到公司强劲的财务状况和潜在的积极发展。该公司还表示，当前股价已反映了预期增长。Piper Sandler对Edwards Lifesciences的股票维持中性立场，强调即将发布的EARLY-TAVR研究结果。

San Francisco, California--(Newsfile Corp. - October 22, 2024) - Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now.

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

The Edwards Lifesciences class action lawsuit further alleges that on July 24, 2024, Edwards Lifesciences disclosed second quarter 2024 TAVR results below expectations and lowered fiscal year 2024 ...